These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19420744)

  • 1. The significance of glycosylation analysis in development of biopharmaceuticals.
    Kawasaki N; Itoh S; Hashii N; Takakura D; Qin Y; Huang X; Yamaguchi T
    Biol Pharm Bull; 2009 May; 32(5):796-800. PubMed ID: 19420744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis.
    Lingg N; Zhang P; Song Z; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1462-72. PubMed ID: 22829536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological significance of glycosylation in therapeutic proteins.
    Li H; d'Anjou M
    Curr Opin Biotechnol; 2009 Dec; 20(6):678-84. PubMed ID: 19892545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.
    Borza B; Szigeti M; Szekrenyes A; Hajba L; Guttman A
    J Pharm Biomed Anal; 2018 May; 153():182-185. PubMed ID: 29499461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample preparation for N-glycosylation analysis of therapeutic monoclonal antibodies by electrophoresis.
    Szekrényes Á; Partyka J; Varadi C; Krenkova J; Foret F; Guttman A
    Methods Mol Biol; 2015; 1274():183-95. PubMed ID: 25673493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human rhabdomyosarcoma cell line TE671--Towards an innovative production platform for glycosylated biopharmaceuticals.
    Rosenlöcher J; Weilandt C; Sandig G; Reinke SO; Blanchard V; Hinderlich S
    Protein Expr Purif; 2015 Nov; 115():83-94. PubMed ID: 26272370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Targeting for Precision Glyco-Engineering: Production of Biopharmaceuticals Devoid of Plant-Typical Glycosylation in Moss Bioreactors.
    Decker EL; Wiedemann G; Reski R
    Methods Mol Biol; 2015; 1321():213-24. PubMed ID: 26082225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using glyco-engineering to produce therapeutic proteins.
    Dicker M; Strasser R
    Expert Opin Biol Ther; 2015; 15(10):1501-16. PubMed ID: 26175280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycan characterization of biopharmaceuticals: Updates and perspectives.
    Planinc A; Bones J; Dejaegher B; Van Antwerpen P; Delporte C
    Anal Chim Acta; 2016 May; 921():13-27. PubMed ID: 27126786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glyco-Engineering Plants to Produce Helminth Glycoproteins as Prospective Biopharmaceuticals: Recent Advances, Challenges and Future Prospects.
    van der Kaaij A; van Noort K; Nibbering P; Wilbers RHP; Schots A
    Front Plant Sci; 2022; 13():882835. PubMed ID: 35574113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTIR spectroscopy as an analytical tool to compare glycosylation in therapeutic monoclonal antibodies.
    Derenne A; Derfoufi KM; Cowper B; Delporte C; Goormaghtigh E
    Anal Chim Acta; 2020 May; 1112():62-71. PubMed ID: 32334683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation of Therapeutic Proteins: A Critical Quality Attribute.
    Delobel A
    Methods Mol Biol; 2021; 2271():1-21. PubMed ID: 33907996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brilliant glycans and glycosylation: Seq and ye shall find.
    Gao G; Li C; Fan W; Zhang M; Li X; Chen W; Li W; Liang R; Li Z; Zhu X
    Int J Biol Macromol; 2021 Oct; 189():279-291. PubMed ID: 34389387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceuticals from plants: a multitude of options for posttranslational modifications.
    Warzecha H
    Biotechnol Genet Eng Rev; 2008; 25():315-30. PubMed ID: 21412360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folding of glycoproteins: toward understanding the biophysics of the glycosylation code.
    Shental-Bechor D; Levy Y
    Curr Opin Struct Biol; 2009 Oct; 19(5):524-33. PubMed ID: 19647993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression systems for therapeutic glycoprotein production.
    Durocher Y; Butler M
    Curr Opin Biotechnol; 2009 Dec; 20(6):700-7. PubMed ID: 19889531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biological role of heterogeneous glycoprotein structures].
    Jakab L
    Orv Hetil; 2016 Jul; 157(30):1185-92. PubMed ID: 27452068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical characterization of biopharmaceuticals.
    Parr MK; Montacir O; Montacir H
    J Pharm Biomed Anal; 2016 Oct; 130():366-389. PubMed ID: 27324698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.